Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

Birla Shloka Edutech fixes FPO price band at Rs 45-50
IT infrastructure provider Birla Shloka Edutech today said it has fixed the price band of it follow-on-public offer between Rs 45 and Rs 50. generic levitra

payday loans online
Tata Motors: Positives priced in
Tata Motor’s future profitability hinges on its ability to scale up JLR volumes and execute a slew of cost-reduction measures.

News of the day

FIIs raise stake in Nifty firms to 43%
Buy shares worth Rs 30,456 crore in June quarter, mostly from open market.
Business Opportunities

Sun Pharma gets tentative FDA nod for generic Gleevec tablets

Sun Pharmaceutical Industries today said it has got tentative approval from the US drug regulator for generic Gleevec (imatinib meyslate tablets), used in the treatment of chronic myeloid leukaemia. - Glenmark Generics gets US FDA nod for Ciclopirox Olamine - Aurobindo gets USFDA nod for hypertension drug - Sun Pharma gains on HC order - HC stops Zydus drug sale on Sun petition - Aurobindo gets USFDA nod for Cefotaxime injection - India Eco Summit: Issues with USFDA to drag on, says Ranbaxy The US Food and Drug Administration (USFDA) has granted tentative approval for the company"s abbreviated new drug application (ANDA) for generic Gleevec, Sun Pharma said in a filing to the Bombay Stock Exchange (BSE). The tentatively approved drug (imatinib meyslate tablets) is therapeutically equivalent to Gleevec tablets of Novartis. The approval of imatinib mesylate tablets are in the strengths of 100 mg and 400 mg. The annual sales of these tablets are about 950 million dollars in the US. Shares of Sun Pharmaceutical were trading at Rs 1,451.90, down 1.74 per cent in the morning trade on the BSE.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009